GYRE

Gyre TX, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing small-molecule therapeutics for organ fibrosis and inflammatory diseases. Its lead product, F351 (hydronidone), is being evaluated for treating metabolic dysfunction-associated steatohepatitis (MASH)-related liver fibrosis in the United States, while in China, it is advancing treatments for chronic hepatitis B-associated liver fibrosis. Gyre also operates Cullgen Inc., which develops targeted protein degrader therapies for cancer and inflammatory conditions.